# US 2025/0367288 A1 · Delivery of multi-cytokine signals by overexpression of wild-type or mutant signal transduction molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367288 A1
- Document ID: US20250367288A1
- Status: Published application
- Kind: A1
- Application number: 18/723,298
- Filed: 2022-12-22
- Published: 2025-12-04
- Earliest claimed: 2021-12-23
- Assignees: The Trustees of the University of Pennsylvania
- Applicants: The Trustees of the University of Pennsylvania
- Inventors: Saar GILL
- Web page: https://patentgrep.com/patent/US20250367288A1

## CPC

- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 38/2086: {IL-13 to IL-16}
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4221: {CD20}
- A61K 40/4251: {Kinases, e.g. Raf or Src}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/2887: {against CD20}
- C12N 5/0636: {T lymphocytes}
- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- C12Y 207/10002: Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
- A61K 2239/23: On/off switch
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/03: containing a transmembrane segment
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present disclosure provides methods for delivering multi-cytokine signals by overexpressing wild-type or mutant signal transduction molecules in lymphocytes (e.g. CAR T cells). Compositions and methods of treatment are also provided.

## Claims

### Claim 1

A method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a modified immune cell or precursor cell thereof comprising a chimeric antigen receptor (CAR) and an overexpressed JAK2, wherein the JAK2 comprises a valine to phenylalanine substitution at codon 617 (JAK2V617F).

### Claim 1

A method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a modified immune cell or precursor cell thereof comprising a chimeric antigen receptor (CAR) and an overexpressed JAK2, wherein the JAK2 comprises a valine to phenylalanine substitution at codon 617 (JAK2V617F).

### Claim 2

A method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a modified immune cell or precursor cell thereof comprising a chimeric antigen receptor (CAR) and an overexpressed JAK3, wherein the JAK3 comprises a methionine to isoleucine substitution at codon 511 (JAK3M511I).

### Claim 2

A method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a modified immune cell or precursor cell thereof comprising a chimeric antigen receptor (CAR) and an overexpressed JAK3, wherein the JAK3 comprises a methionine to isoleucine substitution at codon 511 (JAK3M511I).

### Claim 3

A method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a modified immune cell or precursor cell thereof comprising
a chimeric antigen receptor (CAR) comprising an antigen binding domain, a transmembrane domain, and an intracellular domain, and
a chimeric receptor comprising Granulocyte Colony Stimulating Factor Receptor (G-CSFR), Interleukin-2 Receptor Beta (IL2Rβ), and Interleukin-2 Receptor Gamma (IL2Ry).

### Claim 3

A method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a modified immune cell or precursor cell thereof comprising
a chimeric antigen receptor (CAR) comprising an antigen binding domain, a transmembrane domain, and an intracellular domain, and
a chimeric receptor comprising Granulocyte Colony Stimulating Factor Receptor (G-CSFR), Interleukin-2 Receptor Beta (IL2Rβ), and Interleukin-2 Receptor Gamma (IL2Ry).

### Claim 4 (depends on 1)

The method of claim 1, further comprising administering a cytokine to the subject.

### Claim 4

The method of any preceding claim, further comprising administering a cytokine to the subject.

### Claim 5 (depends on 1)

The method claim 1, further comprising administering a JAK1/2 inhibitor to the subject.

### Claim 5

The method of any preceding claim, further comprising administering a JAK1/2 inhibitor.

### Claim 6 (depends on 5)

The method of claim 5, wherein the JAK1/2 inhibitor is ruxolitinib.

### Claim 6 (depends on 5)

The method of claim 5, wherein the JAK1/2 inhibitor is ruxolitinib.

### Claim 7 (depends on 1)

The method claim 1, wherein the cell is a T cell.

### Claim 7

The method of any preceding claim, wherein the cell is a T cell.

### Claim 8 (depends on 1)

The method claim 1, wherein the cell is an autologous cell.

### Claim 8

The method of any preceding claim, wherein the cell is an autologous cell.

### Claim 9 (depends on 1)

The method claim 1, wherein the disease or disorder is cancer.

### Claim 9

The method of any preceding claim, wherein the disease or disorder is cancer.

### Claim 10

A modified immune cell or precursor cell thereof comprising a chimeric antigen receptor (CAR) and an overexpressed JAK2, wherein the JAK2 comprises a valine to phenylalanine substitution at codon 617 (JAK2V617F).

### Claim 10

A modified immune cell or precursor cell thereof comprising a chimeric antigen receptor (CAR) and an overexpressed JAK2, wherein the JAK2 comprises a valine to phenylalanine substitution at codon 617 (JAK2V617F).

### Claim 11

A modified immune cell or precursor cell thereof comprising a chimeric antigen receptor (CAR) and an overexpressed JAK3, wherein the JAK3 comprises a methionine to isoleucine substitution at codon 511 (JAK3M511I).

### Claim 11

A modified immune cell or precursor cell thereof comprising a chimeric antigen receptor (CAR) and an overexpressed JAK3, wherein the JAK3 comprises a methionine to isoleucine substitution at codon 511 (JAK3M51II).

### Claim 12

A modified immune cell or precursor cell thereof comprising
a chimeric antigen receptor (CAR) comprising an antigen binding domain, a transmembrane domain, and an intracellular domain, and
a chimeric receptor comprising G-CSFR, IL2Rβ, and IL2Ry.

### Claim 12

A modified immune cell or precursor cell thereof comprising
a chimeric antigen receptor (CAR) comprising an antigen binding domain, a transmembrane domain, and an intracellular domain, and
a chimeric receptor comprising G-CSFR, IL2Rβ, and IL2Ry.

### Claim 13 (depends on 10)

The modified immune cell or precursor cell thereof of claim 10, wherein the cell is a T cell.

### Claim 13

The modified immune cell or precursor cell thereof of any preceding claim, wherein the cell is a T cell.

### Claim 14 (depends on 10)

The modified immune cell or precursor cell thereof of claim 10, wherein the cell is an autologous cell.

### Claim 14

The modified immune cell or precursor cell thereof of any preceding claim, wherein the cell is an autologous cell.

### Claim 15 (depends on 10)

The modified immune cell or precursor cell of claim 10, wherein the CAR comprises an antigen binding domain, a transmembrane domain, and an intracellular domain.

### Claim 15

The modified immune cell or precursor cell of any preceding claim, wherein the CAR comprises an antigen binding domain, a transmembrane domain, and an intracellular domain.

### Claim 16 (depends on 15)

The modified immune cell or precursor cell of claim 15, wherein the antigen binding domain is selected from the group consisting of an antibody, an scFv, and a Fab.

### Claim 16 (depends on 15)

The modified immune cell or precursor cell of claim 15, wherein the antigen binding domain is selected from the group consisting of an antibody, an scFv, and a Fab.

### Claim 17 (depends on 16)

The modified immune cell or precursor cell of claim 16, wherein the antigen binding domain is capable of binding a tumor associated antigen (TAA).

### Claim 17 (depends on 16)

The modified immune cell or precursor cell of claim 16, wherein the antigen binding domain is capable of binding a tumor associated antigen (TAA).

### Claim 18

A method of expanding CAR T cells in a subject, the method comprising administering to the subject a modified T cell comprising a CAR and an overexpressed JAK2V617F.

### Claim 18

A method of expanding CAR T cells in a subject, the method comprising administering to the subject a modified T cell comprising a CAR and an overexpressed JAK2V617F.

### Claim 19

A method of expanding CAR T cells in a subject, the method comprising administering to the subject a modified T cell comprising a CAR and an overexpressed JAK3M511I.

### Claim 19

A method of expanding CAR T cells in a subject, the method comprising administering to the subject a modified T cell comprising a CAR and an overexpressed JAK3M511I.

### Claim 20

A method of expanding CAR T cells in a subject, the method comprising administering to the subject a modified T cell comprising a CAR and a chimeric receptor comprising G-CSFR, IL2Rβ, and IL2Rγ.

### Claim 20

A method of expanding CAR T cells in a subject, the method comprising administering to the subject a modified T cell comprising a CAR and a chimeric receptor comprising G-CSFR, IL2Rβ, and IL2Ry.

### Claim 21 (depends on 18)

The method of claim 18, further comprising administering a cytokine to the subject.

### Claim 21 (depends on 18, 19, 20)

The method of any of claims 18-20, further comprising administering a cytokine to the subject.

### Claim 22 (depends on 18)

The method of claim 18, further comprising administering an inhibitor of JAK 2 or JAK1/2 to the subject.

### Claim 22 (depends on 18, 19, 20, 21)

The method of any of claims 18-21, further comprising administering an inhibitor of JAK 2 or JAK1/2 to the subject.

### Claim 23 (depends on 22)

The method of claim 22, wherein the JAK1/2 inhibitor is ruxolitinib.

### Claim 23 (depends on 22)

The method of claim 22, wherein the JAK1/2 inhibitor is ruxolitinib.
